Dual Targeting With an HDAC 6 Inhibitor and Bortezomib in Lymphoma
Published: | Updated:
Jennifer E. Amengual, MD, discusses the study she presented at the 2013 American Society of Hematology (ASH) Annual Meeting. The trial analyzed dual targeting with the HDAC inhibitor ACY-1215 and bortezomib in preclinical models of lymphoma.
